Understanding how long-acting Telacebec works in the body
Official title: Pharmacokinetics of Long-Acting Preparations of Telacebec
Funded at Southern Research Institute · NIH-11164319 · Data updated 2026-11-12
This study is looking at how a new long-lasting HIV treatment called Telacebec works in the body using animal models, so we can learn more about its safety and effectiveness for people living with HIV in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern Research Institute NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $241,962 |
| NIH project number | 75N93021D00010-0-759302400001-1 |
| Project ID | NIH-11164319 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who may benefit from new therapeutic options.
✕Less likely to help
Patients who are not living with HIV or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research investigates the pharmacokinetics of long-acting preparations of Telacebec, a potential treatment for HIV. By studying how the drug is absorbed, distributed, metabolized, and excreted in animal models, researchers aim to gather essential data that could inform future clinical trials. The findings will help in understanding the drug's effectiveness and safety profile, ultimately guiding its development for human use. This research is crucial for advancing new therapies for patients living with HIV.
Why it matters
Potential benefit: If successful, this research could lead to more effective long-acting treatments for HIV, improving patient adherence and outcomes.
How similar studies have gone: Previous research on pharmacokinetics of long-acting HIV treatments has shown promise, indicating that this approach could yield valuable insights.
Where this research is happening
-
Southern Research Institute
Birmingham, United States Active
Researchers
- Principal investigator: Bronner, Raymond — Southern Research Institute
- Study coordinator: Bronner, Raymond
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding how broadly neutralizing antibodies may help HIV cure trials
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.